Clinical Trial Update: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating locoregional HER2-targeted CAR T-cell therapy for pediatric recurrent or refractory central nervous system tumors across multiple histo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Teratoid Rhabdoid Tumor
• Central Nervous System Tumors
• Choroid Plexus Carcinoma
• Ependymoma
• Germ Cell Tumor
• Glioma
• Medulloblastoma
• Primitive Neuroectodermal Tumor

Drugs mentioned

• HER2-targeted CAR T-cell therapy (locoregional) (CAR T-cell therapy targeting HER2)

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Central Nervous System Tumor, Pediatric, Glioma | Phase 1 | Status: ACTIVE_NOT_RECRUITING